Kinnate Biopharma Inc
F:6KB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kinnate Biopharma Inc
Net Change in Cash
Kinnate Biopharma Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kinnate Biopharma Inc
F:6KB
|
Net Change in Cash
$2m
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$295m
|
CAGR 3-Years
19%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$2.8B
|
CAGR 3-Years
-99%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
$515.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
$634.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
Kinnate Biopharma Inc
Glance View
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-03. The Company’s products include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered ulcerative colitis (UC). CDK12 inhibitor candidate to target the treatment of ovarian carcinoma (OC), metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).
See Also
What is Kinnate Biopharma Inc's Net Change in Cash?
Net Change in Cash
2m
USD
Based on the financial report for Dec 31, 2023, Kinnate Biopharma Inc's Net Change in Cash amounts to 2m USD.
What is Kinnate Biopharma Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-22%
The average annual Net Change in Cash growth rates for Kinnate Biopharma Inc have been -81% over the past three years , -22% over the past five years .
